BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21422628)

  • 1. Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer.
    Haroun AA; Hadidy AS; Awwad ZM; Nimri CF; Mahafza WS; Tarawneh ES
    Saudi J Kidney Dis Transpl; 2011 Mar; 22(2):291-7. PubMed ID: 21422628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer detection by prostate-specific antigen-related parameters.
    Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New indicator for prostate gland biopsy when malignancy is in question.
    Haroun AA
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):61-6. PubMed ID: 21196614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
    Kawai M; Okajima K; Kobayashi K; Moriyama M
    Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?
    Ohori M; Dunn JK; Scardino PT
    Urology; 1995 Nov; 46(5):666-71. PubMed ID: 7495118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
    Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
    Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.